Abstract: The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therapeutic agent.

Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.

Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.

Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.

Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

Abstract: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.

Abstract: The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low molecular weight and/or an organic compound from living organisms, preferably from jellyfish, said compound being selected from among collagen, a polysaccharide, a proteoglycan or a mixture of two of said organic compounds, and said molecule having a low molecular weight and formula (I) as defined herein. The invention also relates to a method for removing particles from a liquid medium containing same. The invention is particularly suitable for use in water decontamination and biotechnology.

Abstract: The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof.

Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorisation of therapeutic agents, especially anti-tumoral agents.

Abstract: The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.

Abstract: The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.

Abstract: The invention concerns a method for coating solid particles with a thermofusible agent which consists in: fluidizing the solid particles in an ascending air movement in spiral rotation to obtain a homogeneous individualised distribution of the particles in the air fluidized bed, the temperature of the air fluidized bed being lower than the melting point of the thermofusible agent; spraying on the particles the melted thermofusible agent in the form of atomised droplets, said droplets being distributed in a spraying cone included in an air zone, whereof the temperature enables to maintain, throughout said spraying process, a temperature of the thermofusible agent substantially equal its melting point, the spraying being carried out in the same direction and tangentially to the movement followed by the solid particles; finally, after the coating process, cooling the resulting coated particles so as to solidify the thermofusible agent around the particles.

Abstract: The invention concerns a pellet for immediate release of an active substance to be ingested, said pellet comprising at least one active substance, a binding agent and a diluting agent, characterised in that said binding agent: comprises a mixture of glycerides subjected to polyglycolysis whereof the fatty acids comprise at least 8 carbon atoms; has a melting point not less than 37° C.; has a hydrophilic/lipophilic balance not less than 10, said binding agent being capable of enhancing the active substance bioavailability.

Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant.

Abstract: This invention relates to a programmable adapter device between a higher level communication protocol supported by a higher level equipment (30) and at least one lower level communication protocol supported by a lower level automation equipment (40). The device comprises an adapter (20) provided with a first memory (25) containing a conversion program (15) between the higher level protocol and a lower level protocol, downloadable from the higher level equipment (30) and that can be executed by the adapter (20), and provided with a second non-volatile memory (26) containing a resident driver program (16) in order to initialise communication with the higher level equipment (30). A memory area (17) is used as an intermediate buffer to manage asynchronism between protocols. The lower level connecting cable (14) is used to identify a complete or partial identifier of the lower level protocol.

Abstract: The invention relates to a process for the manufacture of a pharmaceutical composition with modified release of active principle comprising at least one active principle, a lipid matrix agent composed of ester of alcohol with at least one fatty acid and at least one adjuvant. This process is characterized in that: a powder composed of at least one component selected in the group comprising the active principle and the adjuvant, is mixed, while heating and fluidizing, in order to obtain individual grains; the said lipid matrix agent is liquefied separately under warm conditions; the said powder is then coated under warm conditions by spraying the said lipid matrix agent over the individual grains; finally, the temperature of the combined product is lowered in order to allow the lipid matrix agent to solidify.

Abstract: The invention concerns a composition comprising a microemulsion forming system by contact with a hydrophilic phase brought, after ingestion, by the physiological fluid, said microemulsion forming system comprising: at least an active principle; a lipophilic phase; a surfactant (TA); a co-surfactant (CoTA). The invention is characterized in that said composition further comprises an inert polymeric matrix which cannot be ionised at physiological pH, dispersed in the microemulsion forming system before ingestion, said polymeric matrix being capable, after ingestion, of forming on contacting the physiological fluid, a gelled polymeric matrix enabling to release by diffusion, in continuous and prolonged manner the already micro-emulsified active principle.